The purpose of this document is to provide detailed guidance in the review and processing of the form HHS-717-1, Confidential Report of Financial Interests in Substantially Affected Organizations (SAO) for Employees of the NIH. The form will be completed and processed in the order noted below. IC Deputy Ethics Counselors (DECs) have jurisdiction for making the final determination and signing the report for all employees except NIH Senior, who are handled by the NIH Ethics Office (NEO) and the NIH DEC.

**EMPLOYEE**  See separate detailed instructions for the employee. This is a summary only.

**Part I. Employee Information.** The employee will complete Part I.

**Part II. Summary of Conflict of Interest Law.** The employee will read this part.

**Part III. Financial Interests in Substantially Affected Organizations (SAOs):** The employee will complete this part and submit the report to the Ethics Office with jurisdiction:
- All NIH Top 5 and OD (except for DECs) employees will submit their reports to the NEO.
- DECs submit their reports to the Office of the General Counsel, Ethics Division (OGC/ED).
- All other employees submit their reports to their IC Ethics Office (ICEO).

**ETHICS OFFICE REVIEW**

**Initial Technical Review, IC Ethics Office Staff** (includes NEO Staff for Top 5/Senior Employees)

If an IC Ethics Office receives a report from an NIH senior employee, forward the report to the NEO. Staff in the Ethics Office with jurisdiction will conduct an initial review, and finalize the report as follows:

1. **Compare the HHS-717-1 to the employee’s financial disclosure report.** Confirm that all financial interests reported on the HHS-717-1 are also reported on the employee’s financial disclosure report (SF-278 or OGE-450). Confirm that all financial interests in SAOs which are reported on the employee’s financial disclosure report are also reported on the HHS-717-1.

2. **Review the HHS-717-1** and confirm whether each SAO listed meets the definition of an SAO.
   a. If all SAOs reported are listed on the web site, continue with step 3.
   b. If any SAO reported is not listed on the web site, research the company, e.g., via the internet or other means. Forward the information and your evaluation to the NIH Ethics Office (NEO) for concurrence. The NEO will respond within 2 working days to confirm or deny the determination. Once you receive the NEO determination, continue with the next step.

**Example:** The McKesson Company provides infrastructure support for pharmacies, e.g., software for tracking prescriptions. It does not provide medical products. Therefore, McKesson is not considered an SAO.
c. If the financial interest reported is obviously not an SAO, the IC DEC/designee may make that determination and redact the interest, e.g., if a publicly available, diversified mutual fund is reported.

3. **Correct the report as necessary.** Based on the comparison of the HHS-717-1 to the employee’s financial disclosure report and the above step, and with the employee’s permission, correct the report for the employee. Those holdings reported which do not meet the definition of SAO will be redacted. Redact the information across the entire line and initial next to the identification letter in the first column on the report form to indicate who corrected the report. In background notes or information, document the phone call or maintain the electronic mail giving permission to revise an employee’s report. DO NOT attach such information to the form, i.e., do not staple it to the form. Maintain it separately in the file.

   a. If, after corrections, no financial interests in SAOs are reported, treat the HHS-717-1 as having no SAOs and mark the appropriate box and finish processing the report as indicated in Step 4a, below.

   b. If financial interests are listed, continue with Step 4b or 4c, as applicable, below.

4. **Identify whether supervisor review is required.**

   a. **No supervisor review is required.** If either of these situations apply, skip to DEC DETERMINATION section, page 6. Start with #2 in that section.

      • **Reports which indicate no holdings in Substantially Affected Organizations (SAOs):** These reports do NOT require supervisor review.

      • **Reports which indicate SAO holdings, and both of the following conditions apply:**

         » All SAOs included on the report are listed on the NIH Ethics Program SAO web page, or were confirmed as SAOs in the step above; and

         » All SAOs included on the report are valued at or below the *de minimis* for that type of holding, AND the aggregate value for the type of holding regarding parties/non-parties is at or below the applicable *de minimis*. See 5 CFR 2640 Subpart B for *de minimis* values. See also the summary on the web site: [http://ethics.od.nih.gov/topics/deminimis.htm](http://ethics.od.nih.gov/topics/deminimis.htm)

         **Example:** An employee holds stock in 5 publicly traded pharmaceutical companies, each valued at $2500. Each SAO holding is below the $15,000 *de minimis* for securities (stock), AND the aggregate value is less than the $15,000 *de minimis* for matters involving parties. No supervisor review required.

         Because values are below the *de minimis*, no additional conflicts review is needed. Consider whether a cautionary memo should be sent to employees who participate in clinical protocols or other activities with a potential for conflict. Instruct him/her to monitor the values to keep them below the *de minimis*.

   b. **Supervisor review required for reports which indicate SAO holdings, other than the examples above (all other reports):** These reports require a two-level review, first by the IC Ethics Office staff and then by the supervisor. The IC DEC will make the final determination. Continue with Step 5, Initial Conflict Review.
Example: An employee holds stock in 3 publicly traded pharmaceutical companies, each valued at $7,000. Each SAO holding is below the $15,000 de minimis for securities (stock), but the aggregate value is greater than the $15,000 de minimis for matters involving parties. The supervisor must review.

5. Initial Conflicts Review, Ethics Staff
For extramural staff and SF-278/OGE-450 filers who are not clinical investigators, skip to Step #6.

a. Search the NIH Research Protocol database. See Appendix 1 for detailed instructions.

b. Clarify whether conflicts exist for the investigators. Using the results of the above search, work with other DECs to identify all employees who need review by the protocol Principal Investigator.

- To reduce the amount of time for the Protocol Principal Investigator (PPI), the DEC for the IC of the PPI will act as the lead DEC. The lead DEC will collate the list of SAOs from the investigators across all ICs before contacting the PPI to inquire about potential conflicts for the SAOs in question. Information to be shared includes the following: List of SAOs held, by name of SAO only (no employee name associated with an SAO). For example, if the PPI is from the Clinical Center (CC), the CC DEC will gather information about the SAO financial interests for all investigators from EMIS. If any investigator’s list of SAOs in EMIS has not been updated within the past 6 months, the CC DEC will request updated information from each investigator’s DEC. The investigators’ own IC DEC will contact them for updated information, and will enter the updated information into EMIS for review by the CC DEC.

- The PPI’s DEC will contact the PPI, and send a list of SAOs held by all investigators on the protocol. The PPI will indicate by each SAO listed whether it is a party to the matter, whether it is an entity not party to the protocol but which could be affected by the protocol (non-party), or whether the protocol would have no effect on the entity.

- Ethics staff will then compare the annotated list of outside entities returned by the PPI with the employees’ reports and determine if a real or apparent conflict of interest exists by analyzing the value(s) of the SAO(s) listed on the employee’s report against the applicable de minimis for that type of holding.

- Document the results of the comparison and DEC determination on page 13, Additional Space, as shown in the following examples:

Examples:
Employee holds Merck stock, and is personally and substantially involved in a research protocol entitled xxxx, which can directly and predictably affect Merck. Conflict needs resolution.

Employee holds Merck stock, and is personally and substantially involved in a research protocol entitled xxxx, which can directly and predictably affect a competitor, Pfizer, which makes a similar product as that being used in the protocol. Conflict needs resolution.

Employee holds stock in SAOs, none of which can be affected by official participation in a research protocol entitled xxxx. No conflict for this official responsibility.
6. **Prepare the report for supervisor review.** This process assumes that there are some SAOs listed which require supervisor review.

   a. Copy pages 4 and 5 of the form, and the Additional Space page (page 13) if the employee or DEC used this page, or additional pages attached by the employee or DEC. Use the copy to redact information on ownership and value.

   b. For each SAO listed, redact the value (actual dollar amount). Use “White Out” or “Redaction Tape” to cover the amount.

   c. Copy the redacted pages and produce a copy for the supervisor, to include:
      - Page 1, the employee information page
      - Pages 2 and 3, Summary of Conflict of Interest Law
      - Pages 4 and 5, the Employee Financial Interests pages
      - Pages 6 and 7, the Supervisor Review pages
      - Page 13.

7. **Staple the pages of the redacted copy together and send the report to the Supervisor.** Prepare a cover note giving the due date back to you. If a particular supervisor has a large number of reports to review, you may ask to have the reports returned to you in batches rather than all at once when the supervisor finishes reviewing them.

8. **Keep track of reports and remind supervisors** as needed to ensure timely review and return of reports.

**SUPERVISOR REVIEW**

Reports from non-senior NIH employees which list SAO holdings will be forwarded to the supervisor indicated in Part I, Box 10, for a conflict of financial interest review. The employee will have already submitted his/her completed HHS-717-1 to the appropriate Ethics Office, where initial technical and conflicts review have been performed. The supervisor will:

1. **Read the information that the employee is required to read on pages 2 and 3.**

2. **Examine the employee’s current official duties** and identify whether the employee has official responsibilities of significance to the resolution of Government matters that affect any SAO. Keep in mind that the employee’s official responsibilities might directly or indirectly affect an outside organization. Note the affected organizations on the report, e.g., highlight the holdings for easy reference.

   » **Directly affected** outside entities may include those organizations with which the employee has some official interaction, such as a partner in an official collaborative endeavor. These entities may be a ‘party’ to a particular matter, such as a CRADA partner.

   » **Indirectly affected** outside entities includes those organizations which could be affected by the results of a matter, even though the entity may not be involved in the matter. These entities would be considered ‘non-parties’ since they are not part of the particular matter, but could be affected by the outcome. For example, the outcome of a drug trial can affect not only the maker of the drug being tested, but also the maker of a competing drug.
3. **Compare those affected outside organizations** with the financial interests reported on the employee’s HHS-717-1, in Part III (pages 4 and 5).

4. **Read DEC comments on page 13, if any.**

5. **Using information gained in the above steps, complete Part IV of the HHS-717-1:** (pages 6-7)

   a. **Box 1. Description of Potential Conflicts.** Read the instructions and provide the requested evaluation. Describe the potential conflicts. Use the Additional Space on page 13 as needed. Clearly identify your comments as Part IV, #1.

   **Examples:**
   Employee has a financial interest in Merck, which produces a competing drug to one being used in a protocol on which he works. Employee is in charge of data collection on the protocol, which is personal and substantial participation.

   Employee is the PI on a CRADA, has a financial interest in Merck, and the CRADA uses materials from Pfizer, which makes similar materials. As PI, employee makes or oversees all decisions regarding the CRADA.

   b. **Box 2. Resolution of Potential Conflicts:** Read the instructions and provide the requested information. Indicate any concerns and share the evaluation with the DEC regarding resolution of any identified potential conflicts. Respond to all three issues as directed. Use the Additional Space on page 13 as needed. Identify your comments as Part IV, #2a, #2b, or #2c, as appropriate.

   » **Question a. Reassignment of Work to Another Individual:** Read the instructions and indicate whether the work can be reassigned and why.

   **Examples:**
   Employee is a clinical nurse whose function on several protocols is to collect data. The employee’s financial interest in Merck can be affected by one protocol, entitled xxx. Since several clinical nurses function as data collectors across several protocols, this employee can be reassigned to another protocol without harming the integrity of the protocol nor negatively affecting the employee’s workload or that of other data collection staff.

   Employee is PI on a CRADA entitled XX with Pfizer, because of his expertise in that specific area. The outcome of the CRADA can reasonably be expected to affect his own financial interests in Merck. The PI responsibility cannot be reassigned without harming the expected contribution of the protocol.

   » **Question b. Nature of Work Assignments.** Read the instructions and indicate whether the affected work is a critical portion of the employee’s work.

   **Examples:**
   Handling data collection is a major portion of the employee’s work, but it is not critical that the employee do so on this particular protocol.

   The employee’s work as PI is critical to the CRADA, and central to the employee’s research work.
» Question c. Material Impairment of Ability to Perform Duties of Position: Read the instructions and indicate whether the employee’s ability to perform official work would be significantly affected if the employee were removed from performing the official work which affects the outside organization.

Examples:
There would be no significant impairment for the protocol or the employee if the employee is recused from data collection on the particular protocol. Workloads can be realigned to permit employee to work on other protocols.

There would be substantial impairment of the employee’s ability to perform his official duties if he were recused from the CRADA.

6. **Box 3. Comments:** See the instructions. You may also direct the DEC to your comments on Page 13, Additional Space.

7. **Sign and date the report.** Return it to the Ethics Office that sent it to you. Do NOT keep a copy of the report.

**DEPUTY ETHICS COUNSELOR DETERMINATION**

The Ethics Office staff have already performed the initial technical and conflicts review and sent a redacted copy of the report to the supervisor. The IC DEC reviews the supervisor’s evaluations and makes the final determination about conflict and need for further employee action.

1. **Receive Report from Supervisor.** Review the supervisor’s comments. Replace the Supervisor pages (6, 7) (and add the Additional Space, page 13, if the supervisor used page 13) into the original report so that the final report contains original signatures of the employee and the supervisor. Save the redacted pages separate from the final form to document what was sent to the Supervisor.

2. **Complete the Report.**
   
a. **Complete Part V, as follows:**
   
   » Name of DEC: Self explanatory
   
   » Contact Information: Self explanatory.
   
   » Title of DEC: Official position title. DEC is a function of an employee with another official title, such as Executive Officer, Assistant Director, etc.
   
   » Organization: Enter the full organizational name and address for the DEC.
   
   b. **Read the statements carefully and mark the appropriate box(es):** The DEC will review the evaluations and comments, and make the final determination by marking the appropriate boxes.
   
   - **Total Divestiture of Specified Interests:** Check this box to instruct the employee to divest the full amount of certain types of holdings as identified in the boxes below this section. Use the identification letters associated with each listed interest.
   
   - **Partial Divestiture:** Check this box to instruct the employee to divest down to a certain level (i.e., the *de minimis*). Indicate the letter identification for each holding that must be partially divested.
• **Partial Divestiture by Senior NIH Employees:** Check this box and indicate the letter identification of each prohibited financial interest which the NIH Senior Employee must divest down to the *de minimis* level.

• **Recusal with respect to Particular Matters:** Check this box and indicate the letter identification of each SAO which the employee may retain, but the employee must be recused from all official particular matters involving that specific SAO.

• **Divestiture or Recusal Not Required:** Check this box if the identified holdings pose no conflict and the employee does not have to divest the holding nor recuse him/herself from official particular matters involving the entities listed.

• **Divestiture or Recusal Not Required:** Check this box if the employee reports no financial interests in SAOs in Part III.

• **Other Disposition:** Check this box if some other resolution is being used, and describe that resolution on the blank page 13. Clearly identify the comments as “Part V, Other Disposition.” For example, the NIH DEC may recommend a waiver to resolve an identified conflict.

3. **Sign and date the report; return it to Ethics Office staff to finalize.**

**ETHICS OFFICE STAFF FINALIZE REPORT**

These instructions also apply to the NEO staff (for NIH Senior staff) and to the Office of the General Counsel, Ethics Division (for Deputy Ethics Counselors).

1. **Review DEC Determinations:**

   a. If there are no required employee actions, continue with step #7 below, in this section.

   b. If the employee must divest or take other remedial action, retain the original and return a copy to the employee with instructions to review the DEC Determination in Part V, and to follow the employee instructions for Parts VI and VII. Give a deadline of 2 weeks to request a CD. For NEO and OGC/ED, send a copy to the employee’s IC Ethics Office for information.

2. **Periodically follow up with employee** to check on progress, e.g., weekly. If the employee wishes to request a Certificate of Divestiture (CD), the employee must notify the DEC within 2 weeks of the DEC signature in Part V by returning the original form with the CD request, as outlined in Part VI, box 2 of the form.

3. **Receive Signed Part VI, Certificate of Divestiture from the Employee:** Confirm that the employee checked the appropriate box, signed the report, and provided the additional information as needed. Insert the signed page into the original report and discard the blank page.

   » If the employee requests a CD, continue with the next step.

   » If the employee does NOT request a CD, continue with step #5 below, in this section.

4. **Employee Requests a CD:**

   a. Immediately initiate the CD request package with input from the employee and the Office of the General Counsel, Ethics Division (OGC/ED). Submit the request package to OGC/ED as soon as it is complete.
b. When the CD approval/disapproval document is received, forward it to the employee with a copy of page 11, Part VII. Compliance.

c. Follow up with employee to remind him/her of the divestiture deadline, normally 90 days after the OGE approval date.

d. If other actions (e.g., recusal) are also required, remind the employee of the need to quickly comply with those requirements.

e. Continue with step 6.

5. **Employee Does Not Request a CD:** At this point, the employee has NOT requested a CD:

   » If the employee has NOT submitted a signed Part VII. Compliance page, add the signed Part VI. Certificate of Divestiture to the original report and discard the blank page. Remind the employee of the need to divest within 90 days, and to comply with the other remedial requirements as quickly as possible. Continue with the next step in this section.

   » If the employee does not need to divest and submits a signed Part VII. Compliance, continue to step #6 below, in this section.

6. **Receive Signed Part VII. Compliance From the Employee:** Upon receipt of the signed page, insert the signed Part VII (page 10) into the original report form and discard the blank page. Confirm that your copy has all the original pages.

7. **Enter data in EMIS.** Applicable to all offices which handle the reports (ICEO, NEO, OGC/ED).

8. **Copy the complete report and distribute as directed below:**

   a. **IC Ethics Office for Non-senior employees:** The employees’ ethics files are maintained by the IC Ethics Office. Send a copy to the employee; file the original in the employee’s ethics file.

   b. **NEO for Senior (Top 5) employees:** The employees’ ethics files are maintained in the NEO. Make two copies and forward them to the IC Ethics Office, who will file one copy in the employee’s ethics file there, and send a copy to the employee.

   c. **OGC/ED for DECs:** The original is filed in the employee’s financial disclosure file in OGC Ethics Division. Make two copies, one for the employee and one for the appropriate ethics office (NEO for Senior; IC Ethics Office for others).

**NOTE TO ALL ETHICS STAFF:**

When filing the final HHS-717-1, include ONLY the original pages in the form. All copies used to obtain supervisor review, all electronic messages, all documentation of phone calls, and other information used to conduct the review are NOT part of the form and must not be stapled or otherwise attached to the final HHS-717-1. Such collateral information may be saved in the employee’s ethics file, appropriately labeled. To attach any additional information to the form makes that additional information legally part of the form, and subject to release if the form is released.
Appendix 1, NIH Protocol Query System (Active Intramural Research Protocols)

The content for the NIH Protocol Query System (PQS) application is a subset of data from the database Protrak, maintained by the Office of Protocol Services (OPS), in the NIH Clinical Center. The site is updated nightly reflecting changes in the protocol actions submitted and approved by the Intramural Institutional Review Board (IRB) and processed by the OPS. The PQS permits ethics staff to identify any official participation in protocols which involve outside entities. The application is available on the NIH intranet (accessible only from NIH computers) at:  http://pqs.cc.nih.gov

The application provides 3 search options:
1. Institute of the Principal Investigator
2. Investigator last name
3. Protocol number

Search Instructions

1. Open the web site and logon.
2. Select the type of search desired from the drop down box.
3. Enter the search criteria:
   a. To retrieve by the IC of the Principal Investigator (PI), enter the IC’s PQS abbreviation, i.e.,:
      CC    CC    NIAAA    AA    NIDCR    DC
      NCI   C     NIAID    I     NIEHS    E
      NHGRI HG    NIAMS    AR    NIMH     M
      NEI   EI    NICHD    CH    NINDS    N
      NHLBI H    NIDCD    DC    NINR     NR
      NIA   AI    NIDDK    DK    NCCAM    AT
   b. To retrieve by PI last name, enter the last name, e.g., Smith.
   c. To retrieve by specific protocol, enter the full protocol number, e.g, 99-C-0058. The sections of the entire protocol number are defined as follows:
      • The first two digits of the protocol number represent the fiscal year during which the protocol was implemented.
      • The next one/two letter(s) represent the IC financially responsible for the protocol.
      • The remaining four digits provide a sequential number assigned to the protocol by the Office of Protocol Services (OPS) in the Clinical Center.
      Protocols in which patients are not seen at the Clinical Center will have either the fiscal year preceded by the letters “OH" (i.e., OH99-C-0083), or the letter “N” preceding the sequential number of the protocol number (i.e., 99-C-N083).
   d. To retrieve IC protocols by year, enter just year and IC, e.g., 05-CC.
4. Click on “Search.”

Sort Order of Results

The results for each search will be ordered according to:

• Search by IC: results are sorted by protocol number, from newest to oldest.
• Search by Investigator: results are sorted alphabetically by investigators’ last name, first name, and within by protocol number from newest to oldest.

Content of Results

Results of the search include the following information:

Protocol # NIH Intramural protocol number
Title Official title of the study
IRB The Institutional body responsible for the regulatory oversight of the protocol.

Investigator List
Contains the investigators associated with the protocol, identifying:
• Name
• Role: Association to the protocol
  » PI: Principal Investigator
  » AI: Associate Investigator
  » MAI: Medically Advisory Investigator
  » RC: Research Contact
• Start Date: Reflects the date on which the investigator was first identified in one of the four roles. Dates were retrospectively entered for investigators serving as PIs, using the earliest date in which s/he started. The date 11/1/05, point of implementation, is reflective as the start date for Investigators who are not PIs. The actual date an investigator assumed responsibility in one of the 4 roles will be used from this point forward for any new investigators.
• IND/IDE List: Identifies investigational drugs/devices identified by the PI on the initial/continuing review protocol application.
• Commercial Entities: identifies commercial or other entities providing the IND/IDE as identified by the PI on the initial or continuing review protocol application.
• Precis: The scientific summary of the protocol.

Assistance

Questions may be addressed to and assistance obtained from:

Kim Jarema Office of Protocol Services 301-435-2401 kjarema@cc.nih.gov